Navigation Links
Sinovac Reports Unaudited Third Quarter 2013 Financial Results
Date:11/12/2013

BEIJING, Nov. 12, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for for the three and nine months ended September 30, 2013.

2013 Third Quarter Financial Highlights (period-over-period comparisons to third quarter 2012)

  • Total quarterly sales increased by 54.5% to $22.1 million from $14.3 million. Excluding $3.6 million of H5N1 vaccine revenue recognized in the third quarter of 2013, the sales from regular products increased by 29.5% to $18.5 million from $14.3 million.
  • Gross profit increased by 111.7% to $15.9 million from $7.5 million. Gross margin was 72.1%, compared to 52.6%.
  • Net income attributable to common stockholders was $2.3 million, or $0.04 per basic and diluted share, compared to net loss attributed to common stockholders of $3.0 million, or $0.05 per basic and diluted share.
  • Cash and cash equivalents totaled $89.0 million as of September 30, 2013, compared to $91.2 million as of December 31, 2012.
  • Recent Business HighlightsIn August 2013, Sinovac (the "Company") was selected by the Beijing Health Bureau as one of the four suppliers to supply the Company's seasonal influenza vaccine, Anflu, to the citizens of Beijing. Sinovac has been chosen as one of the suppliers in the Beijing tender on six separate occasions since 2007. The total volume for the 2013 tender is up to 1.8 million doses and the delivery will depend on the actual demand in Beijing. Under the prior year's tender that totaled up to 1.8 million doses, Sinovac delivered approximately 340,000 doses of Anflu to Beijing citizens. 

    In October 2013, Sinovac was selected by the Jiangsu Centers for Disease Control and Prevention as one of the two suppliers of inactivated hepatitis A vaccine to the pediatric population in
    '/>"/>

    SOURCE Sinovac Biotech Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
    2. Sinovac Reports Unaudited First Quarter 2012 Financial Results
    3. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
    4. Sinovac Schedules 2012 Annual Meeting of Shareholders
    5. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
    6. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
    7. Sinovac Holds 2012 Annual General Meeting of Shareholders
    8. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
    9. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
    10. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
    11. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
    (Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
    (Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
    Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
    ... Jan. 27, 2012 Neurodevice firm ... Series B investment round led by ... 2011, and secured non-dilutive funding of ... million Innovation Ohio loan and a ...
    ... GAITHERSBURG, Md., Jan. 27, 2012 GenVec, Inc. (Nasdaq: ... proprietary technologies to create superior therapeutics and vaccines, today ... License Agreement with Novartis (NYSE: NVS).  Under the extension, ... to support its hearing loss and balance disorders program. ...
    Cached Medicine Technology:Neurodevice Firm Checkpoint Surgical Raises $3M 2GenVec Extends Research Collaboration with Global Pharmaceutical Company 2GenVec Extends Research Collaboration with Global Pharmaceutical Company 3
    (Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
    (Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
    (Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
    (Date:4/17/2014)... 2014While 94 per cent of Canadians surveyed said they ... for a specific number of genetic conditions, only 80 ... in screening that would sequence their newborns, genomes.,Most newborns ... their first day or two of life in which ... heels and tested for about five to 54 conditions, ...
    (Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
    Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3
    ... its spa/gourmet green tea at the Las Vegas IECSC, ... the,International Esthetics, Cosmetics & Spa Conference (IECSC) in Las ... will feature one,product unique for its simplicity: green tea. ... Shinwa, an all-natural, organic,green Japanese karigane tea, at the ...
    ... - SXC Health Solutions, Corp.,("SXC" or the "Company") ... provider of,technology and pharmacy benefits management services, announces ... awarded a,three-year $35 million Pharmacy Benefits Manager (PBM) ... ("TennCare")., Under terms of the proposed agreement, ...
    ... 23 , - Special Library Association (SLA) ... Anniversary of SLA and Honor Two,Lifetimes of Achievement, ... John,and Jean Piety on being this year,s recipients ... of the Year Award. Mr.,and Mrs. Piety,s contributions ...
    ... MONDAY JUNE 23, 2008 , LOW SOCIOECONOMIC STATUS INCREASES ... with low socioeconomic status (SES) have more advanced cancers at ... of dying in the five years following cancer diagnosis, according ... the August 1, 2008 issue of CANCER , a ...
    ... women are struggling with the health fallout caused by a ... -- Most women don,t need a survey to tell them ... feel too sluggish to make it through the day with ... single moms, empty-nesters or grandmothers, many -- if not most ...
    ... (formerly,Diagnostic Ultrasound Corp.), the maker of BladderScan(R) bladder ... selection, for the second year in a row, ... in Washington State by Washington CEO Magazine., ... as the 4th "Best Company To Work For" ...
    Cached Medicine News:Health News:Health and Beauty Come Full Circle: Chado-En Brings Full Benefit of Japanese Green Tea to Spas 2Health News:SXC Health Solutions announces three-year $35 million PBM contract with the State of Tennessee 2Health News:John & Jean Piety Named SLA Engineering Librarians of the Year 2Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 2Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 3Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 4Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 5Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Verathon Inc., Recognized, Second Year Running, as Outstanding Workplace in Washington State by Washington CEO Magazine 2
    ... unique thread design is the ultimate anchor ... to pull out, proven delivery, two sutures ... This provides the orthopedic surgeon a superior ... , ,The TwinFix AB anchor was developed ...
    ... ConTack Labral Anchor is an L-PLA ... for soft tissue reattachment to bone. ... the bony contour of the glenoid, ... Radial Osteo Compression (ROC) design to ...
    ... can be used for open or arthroscopic ... a sterile disposable inserter. The unique deployment ... insertion of the anchor into bone. ... allows for the two pre-threaded sutures to ...
    ... TACIT Threaded Anchor and ... in craniofacial and hand ... secure tissue reattachment and ... The small size facilitates ...
    Medicine Products: